Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients

Molecular Oncology
K SimpsonDuncan M Baird

Abstract

Telomere dysfunction and fusion can drive genomic instability and clonal evolution in human tumours, including breast cancer. Telomere length is a critical determinant of telomere function and has been evaluated as a prognostic marker in several tumour types, but it has yet to be used in the clinical setting. Here we show that high-resolution telomere length analysis, together with a specific telomere fusion threshold, is highly prognostic for overall survival in a cohort of patients diagnosed with invasive ductal carcinoma of the breast (n = 120). The telomere fusion threshold defined a small subset of patients with an extremely poor clinical outcome, with a median survival of less than 12 months (HR = 21.4 (7.9-57.6), P < 0.0001). Furthermore, this telomere length threshold was independent of ER, PGR, HER2 status, NPI, or grade and was the dominant variable in multivariate analysis. We conclude that the fusogenic telomere length threshold provides a powerful, independent prognostic marker with clinical utility in breast cancer. Larger prospective studies are now required to determine the optimal way to incorporate high-resolution telomere length analysis into multivariate prognostic algorithms for patients diagnosed with brea...Continue Reading

References

Jan 17, 1996·Journal of the National Cancer Institute·E HiyamaJ W Shay
Jun 19, 1996·Journal of the National Cancer Institute·K Mokbel, M Ghilchik
Apr 4, 1998·Annals of Surgical Oncology·A S PearsonT J Fahey
Dec 26, 2001·Gynecologic Oncology·Shi-Jun WangNoriyuki Inaba
Jan 23, 2003·Nature Genetics·Duncan M BairdDavid Kipling
Feb 26, 2004·The American Journal of Pathology·Alan K MeekerPedram Argani
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alan K MeekerAngelo M De Marzo
Aug 10, 2004·Nature Genetics·Koei ChinStephen J Lockett
Feb 19, 2005·Current Treatment Options in Oncology·Deepa S Subramaniam, Claudine Isaacs
Sep 17, 2005·Genes & Development·Titia de Lange
Jun 6, 2006·Breast Cancer Research and Treatment·Colleen A FordyceJeffrey K Griffith
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher M HeaphyJeffrey K Griffith
May 8, 2009·Biochimica Et Biophysica Acta·Ulrika Svenson, Göran Roos
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
May 4, 2010·Molecular Oncology·Kevin A KweiJonathan R Pollack
Dec 6, 2011·Nucleic Acids Research·Maira TankimanovaDuncan M Baird
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Cristian BoboilaBjoern Schwer
Aug 15, 2012·Proceedings of the National Academy of Sciences of the United States of America·Hiromi TanakaDavid Gilley
Aug 7, 2013·Journal of the National Cancer Institute·Laureline RogerDuncan M Baird
Sep 17, 2013·Breast Cancer Research and Treatment·Beatriz Martinez-DelgadoJavier Benitez

❮ Previous
Next ❯

Citations

Dec 22, 2015·Cell·John MaciejowskiTitia de Lange
May 12, 2016·Nature Reviews. Molecular Cell Biology·Eros Lazzerini-Denchi, Agnel Sfeir
May 31, 2016·Cell Reports·Alexandra M PinzaruEros Lazzerini Denchi
Oct 28, 2016·The Journal of Pathology. Clinical Research·Mathilde Gay-BellileAndreï Tchirkov
Jan 18, 2017·Nature Reviews. Molecular Cell Biology·John Maciejowski, Titia de Lange
Feb 9, 2018·International Journal of Molecular Sciences·Kez ClealDuncan Baird
Nov 20, 2015·Nature Structural & Molecular Biology·Nausica Arnoult, Jan Karlseder
Jan 18, 2018·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Duncan M Baird
Jan 4, 2018·Blood Advances·Peter M Lansdorp
Apr 30, 2017·Oncotarget·Rhiannon E JonesMeena Upadhyaya
Mar 28, 2017·British Journal of Haematology·Sam HyattDuncan M Baird
Oct 14, 2017·Genome Research·Jennifer McCaffreyMing Xiao
Dec 28, 2018·Nucleic Acids Research·Kate LiddiardDuncan M Baird
Mar 21, 2019·Biology Letters·Stefania Casagrande, Michaela Hau
Aug 30, 2019·Acta Neuropathologica Communications·Fausto J RodriguezChristopher M Heaphy
Mar 24, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Christopher M HeaphyFausto J Rodriguez
Sep 30, 2016·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Kaoutar Ennour-IdrissiCaroline Diorio
Jan 23, 2021·Human Molecular Genetics·Chloé SubeczLauréline Roger
Apr 16, 2020·Trends in Genetics : TIG·Kez Cleal, Duncan M Baird
Jul 30, 2021·Obstetrical & Gynecological Survey·Fabiana B KohlrauschDavid L Keefe

❮ Previous
Next ❯

Software Mentioned

SAS
Prism
SPSS
STELA

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2022 Meta ULC. All rights reserved